Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a woman who experienced worsened breast implant illness symptoms following a COVID-19 infection and vaccination, which improved after implant removal, even though numerous screenings had been inconclusive prior to explantation.

This article reviews the impact of Covid-19 vaccinations on disease severity and mortality, noting challenges with new virus mutations and the importance of vaccine compatibility for future efficacy, but reports no new clinical results.

This report describes a rare case of pityriasis rosea-like eruption in a 52-year-old Thai woman following Oxford/AstraZeneca COVID-19 vaccination, emphasizing the condition does not preclude further vaccinations.

This case study describes a 53-year-old woman who developed severe muscle weakness, myalgia, and alopecia after receiving the Pfizer SARS-CoV-2 vaccine, with partial hair regrowth observed after six months.

This study outlines new strategies for overcoming "cold" tumors, which are typically unresponsive to cancer immunotherapy, with approaches like dendritic cell-based treatments and local immune microenvironment modification, bolstered by both preclinical and clinical trial data.

The authors concluded that there is no increased association between COVID-19 vaccination and alopecia areata, and the overall incidence of the condition in vaccinated individuals matches historical controls.

This study found that engineered extracellular vesicles (293F-EGF-EV), enriched in EGF mRNA, significantly aided skin wound healing in vitro and in a rat model by promoting fibroblast activity and improving wound recovery through processes like angiogenesis and reduced scarring.

This review discusses vaccine safety concerns for individuals with autoimmune and inflammatory conditions, noting vaccine hesitancy due to observed exacerbations post-vaccination and a lack of comprehensive trial data.

This study reported cases of post-vaccine telogen effluvium and alopecia among five individuals in Ecuador following a mixed COVID-19 vaccination regimen, typically appearing within 3 to 17 days after inoculation.

This study reported that alopecia areata following COVID-19 vaccination is rare, occurring mostly after the first dose and associated with several vaccine types, particularly Pfizer.

This study found that COVID-19 vaccination initially lowered vitamin D levels in serum and hair but increased serum levels after the second dose, except for the Pfizer group. Hair vitamin D showed a nonsignificant increase, and hair loss was most common with the AstraZeneca vaccine.

In this study, patient-reported flare symptoms after COVID-19 vaccination in individuals with systemic lupus erythematosus were generally mild, with 17% experiencing flares mostly characterized by joint pain and fatigue; vaccine type did not affect flare incidence.

This study concluded that the anti-SARS-CoV-2 vaccine does not significantly increase the risk of flares in patients with hidradenitis suppurativa.

This study described cases of alopecia areata occurring after COVID-19 vaccination and highlights management using both topical and systemic therapies.

In this study, transcutaneously applied nanoparticles and viral vectors were shown to penetrate murine hair follicles, internalize in antigen-presenting cells, and induce immune responses, suggesting a promising approach for vaccine delivery.

In this study, nearly two-thirds of Saudi adults reported experiencing hair loss following COVID-19 infection or vaccination, with female sex and nutritional deficiencies identified as significant correlates for this condition.

This study suggests that transfection with modified KGF-mRNA enhances keratinocyte reepithelialization in wound therapy by temporarily increasing growth factor expression without affecting nuclear DNA.

This study observed that COVID-19 patients in Thailand infected with the Delta variant were more likely to develop pneumonia and certain post-infection conditions, while Omicron infections were associated with milder symptoms like sore throat and congestion.

This report observed a case of pilomatrixoma appearing at the COVID-19 vaccination site of a 65-year-old man, aligning with previous findings that suggest a potential association between vaccination sites and this benign tumor.

This study found that COVID-19 vaccines were generally well-tolerated among Bangladeshi medical students, with most side effects being mild and decreasing in frequency after subsequent doses.

In this case report, a 56-year-old Black man experienced patchy scalp hair loss which began four months after his second COVID-19 vaccination, also considering his medical history of hypertension and type 2 diabetes.

This study reports that comorbidities and anti-androgen therapy were associated with lower SARS-CoV-2 vaccination rates among patients with androgenetic alopecia, emphasizing the need to promote vaccination within this group.

This study reported a series of mild to moderate cutaneous adverse drug reactions following COVID-19 vaccination, predominantly after Covishield, with only one requiring hospitalization.

This study observed a high prevalence of hair loss among adults after receiving COVID-19 vaccination, with two-thirds of participants experiencing this issue and a minority of cases possibly vaccine-related.

This study observed a low rate of long-COVID lasting more than three months among mostly vaccinated healthcare workers during the Omicron wave, suggesting that further research is needed to assess the impact of different vaccines on long-COVID-19 in this group.

This study found that RCS-01 cell therapy for aged skin was well tolerated and associated with increased gene expression related to extracellular matrix homeostasis, suggesting potential skin improvement.

This study found that a single instance of acute skin stretching can enhance immune surveillance and improve vaccine delivery by increasing skin permeability and promoting immune cell recruitment without causing tissue damage.

COVID-19 vaccines can cause minor skin reactions, including those related to Bullous Pemphigoid, but these usually resolve on their own.

This review discusses various types of hair loss associated with COVID-19 and vaccinations, highlighting acute telogen hair loss as the most common form, but reports no new clinical results.

This study found that COVID-19 vaccine booster dose acceptance was high in the East Mediterranean Region, especially among those informed by the Ministry of Health, but concerns about benefits and side effects influenced rejection.